Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European countries to make sure they are also funding their “fair share” of biopharma innovation.
Bayer’s Continued Restructuring Claims 2,000 Jobs and Thins Management Layers